Solutions and aerosols of metal-containing compounds
View Patent ↗Solutions and aerosols of metal-containing compounds are disclosed. Methods of preparing and using the solutions and aerosols, particularly in the treatment of a subject having a condition, are also disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.
1. A pharmaceutical composition, comprising:
a pharmaceutically acceptable carrier selected from the group consisting of DMSO and liposomes; and
a silver-containing compound in the pharmaceutically acceptable carrier;
wherein:
the pharmaceutical composition comprises from about 0.01 weight percent to about 5 weight percent of the silver-containing compound;
when said pharmaceutically acceptable carrier is DMSO, DMSO is present in an amount sufficient to assist in the penetration of skin and the silver-containing compound is selected from the group consisting of nanocrystalline silver-containing compounds and atomically disordered silver-containing compounds; and
when said pharmaceutically acceptable carrier is a liposome, the silver-containing compound is selected from the group consisting of atomically disordered silver-containing compounds.
2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least about 0.1 weight percent of the silver-containing compound.
3. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least about 0.5 weight percent of the silver-containing compound.
4. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least about 0.75 weight percent of the silver-containing compound.
5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least about one weight percent of the silver-containing compound.
6. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least about two weight percent of the silver-containing compound.
7. The pharmaceutical composition of claim 1 , wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides, silver nitrides, silver borides, silver halides and silver hydrides.
8. The pharmaceutical composition of claim 1 , wherein the silver-containing compound is selected from the group consisting of atomically disordered silver oxides.
9. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides, silver nitrides, silver borides, silver halides and silver hydrides.
10. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound is selected from the group consisting of nanocrystalline silver oxides.
11. The pharmaceutical composition of claim 1 , wherein the silver-containing compound is nanocrystalline silver and the pharmaceutically acceptable carrier is DMSO.
12. The pharmaceutical composition of claim 1 , wherein the silver-containing compound is a nanocrystalline silver oxide and the pharmaceutically acceptable carrier is DMSO.
13. The pharmaceutical composition of claim 1 , wherein the silver-containing compound is atomically disordered silver.
14. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is a liposome.
15. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is in the form of a sustained release article.
16. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent nanocrystalline silver.
17. The pharmaceutical composition of claim 16 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
18. The pharmaceutical composition of claim 16 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
19. The pharmaceutical composition of claim 16 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
20. The pharmaceutical composition of claim 16 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.
21. The pharmaceutical composition of claim 1 , wherein the silver-containing compound present in the composition is at least about 0.1 weight percent atomically disordered silver.
22. The pharmaceutical composition of claim 21 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
23. The pharmaceutical composition of claim 21 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
24. The pharmaceutical composition of claim 21 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
25. The pharmaceutical composition of claim 21 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.
26. The pharmaceutical composition of claim 1 , wherein the silver-containing compound present in the composition is at least about 0.1 weight percent atomically disordered silver oxide.
27. The pharmaceutical composition of claim 26 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
28. The pharmaceutical composition of claim 26 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
29. The pharmaceutical composition of claim 26 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
30. The pharmaceutical composition of claim 26 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.
31. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver oxide.
32. The pharmaceutical composition of claim 31 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
33. The pharmaceutical composition of claim 31 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
34. The pharmaceutical composition of claim 31 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
35. The pharmaceutical composition of claim 31 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.
36. The pharmaceutical composition of claim 1 , wherein the pharmaceutically acceptable carrier is DMSO and the silver-containing compound present in the composition is at least about 0.1 weight percent of a nanocrystalline silver compound.
37. The pharmaceutical composition of claim 36 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
38. The pharmaceutical composition of claim 36 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
39. The pharmaceutical composition of claim 36 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
40. The pharmaceutical composition of claim 36 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.
41. The pharmaceutical composition of claim 1 , wherein the silver-containing compound present in the composition is at least about 0.1 weight percent of an atomically disordered silver compound.
42. The pharmaceutical composition of claim 41 , wherein the silver-containing compound present in the composition is at least about 0.5 weight percent.
43. The pharmaceutical composition of claim 41 , wherein the silver-containing compound present in the composition is at least about 0.75 weight percent.
44. The pharmaceutical composition of claim 41 , wherein the silver-containing compound present in the composition is at least about 1 weight percent.
45. The pharmaceutical composition of claim 41 , wherein the silver-containing compound present in the composition is at least about 2 weight percent.